Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...
NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare ...
Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. ...
Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its markete...
Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two...
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, announced a research program under its strategic collabora...
SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gast...
Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the expansion...
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 Sanofi announced that it has entered in...
Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) shares positive top-line results of a Phase II clinical tri...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of CDC-like kinases (C...
Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, announced a co-marketing agreement with Agilent Technologies to ...
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional inv...
© 2025 Biopharma Boardroom. All Rights Reserved.
